Injectable In Situ Gelling System for Sustained Nicotine Delivery as a Replacement Therapy for Smoking Cessation
Nicotine replacement therapy (NRT) is widely used to limit the withdrawal symptoms associated with cigarette smoking cessation. However, the available NRT formulations are limited by their short release profiles, requiring frequent administrations along with local side effects. Thus, the objective o...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Gels |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2310-2861/8/2/114 |
| _version_ | 1797480008252391424 |
|---|---|
| author | Eileen Hulambukie Hani Abdeltawab Sanjukta Duarah Darren Svirskis Manisha Sharma |
| author_facet | Eileen Hulambukie Hani Abdeltawab Sanjukta Duarah Darren Svirskis Manisha Sharma |
| author_sort | Eileen Hulambukie |
| collection | DOAJ |
| description | Nicotine replacement therapy (NRT) is widely used to limit the withdrawal symptoms associated with cigarette smoking cessation. However, the available NRT formulations are limited by their short release profiles, requiring frequent administrations along with local side effects. Thus, the objective of this study is to develop an NRT formulation that offers prolonged, sustained nicotine release. Thermoresponsive in situ gelling systems containing nicotine were prepared using poloxamer 407 (P407) and poloxamer 188 (P188). The system was optimized using a three-factor, two-level full factorial design (2<sup>3</sup>). A formulation composed of P407 (20% <i>w/w</i>), P188 (5% <i>w/w</i>), and loaded with nicotine (0.5% <i>w/w</i>) exhibited sol-to-gel transition at a suitable temperature close to physiological temperature (30 °C). The rheological analysis demonstrated a Newtonian-like flow at room temperature, suggesting ease of administration via injection, and semisolid gel status at physiological temperature. The optimized formulation successfully sustained nicotine in vitro release over 5 days following single administration. The findings suggest that poloxamer based in situ gelling systems are promising platforms to sustain the release of nicotine. |
| first_indexed | 2024-03-09T21:53:57Z |
| format | Article |
| id | doaj.art-96d8092f58984c258a3e4faa3a6a6972 |
| institution | Directory Open Access Journal |
| issn | 2310-2861 |
| language | English |
| last_indexed | 2024-03-09T21:53:57Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Gels |
| spelling | doaj.art-96d8092f58984c258a3e4faa3a6a69722023-11-23T20:02:01ZengMDPI AGGels2310-28612022-02-018211410.3390/gels8020114Injectable In Situ Gelling System for Sustained Nicotine Delivery as a Replacement Therapy for Smoking CessationEileen Hulambukie0Hani Abdeltawab1Sanjukta Duarah2Darren Svirskis3Manisha Sharma4School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New ZealandSchool of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New ZealandSchool of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New ZealandSchool of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New ZealandSchool of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland 1142, New ZealandNicotine replacement therapy (NRT) is widely used to limit the withdrawal symptoms associated with cigarette smoking cessation. However, the available NRT formulations are limited by their short release profiles, requiring frequent administrations along with local side effects. Thus, the objective of this study is to develop an NRT formulation that offers prolonged, sustained nicotine release. Thermoresponsive in situ gelling systems containing nicotine were prepared using poloxamer 407 (P407) and poloxamer 188 (P188). The system was optimized using a three-factor, two-level full factorial design (2<sup>3</sup>). A formulation composed of P407 (20% <i>w/w</i>), P188 (5% <i>w/w</i>), and loaded with nicotine (0.5% <i>w/w</i>) exhibited sol-to-gel transition at a suitable temperature close to physiological temperature (30 °C). The rheological analysis demonstrated a Newtonian-like flow at room temperature, suggesting ease of administration via injection, and semisolid gel status at physiological temperature. The optimized formulation successfully sustained nicotine in vitro release over 5 days following single administration. The findings suggest that poloxamer based in situ gelling systems are promising platforms to sustain the release of nicotine.https://www.mdpi.com/2310-2861/8/2/114nicotinesustained releaseprolonged releasepoloxamersdesign expertfactorial design |
| spellingShingle | Eileen Hulambukie Hani Abdeltawab Sanjukta Duarah Darren Svirskis Manisha Sharma Injectable In Situ Gelling System for Sustained Nicotine Delivery as a Replacement Therapy for Smoking Cessation Gels nicotine sustained release prolonged release poloxamers design expert factorial design |
| title | Injectable In Situ Gelling System for Sustained Nicotine Delivery as a Replacement Therapy for Smoking Cessation |
| title_full | Injectable In Situ Gelling System for Sustained Nicotine Delivery as a Replacement Therapy for Smoking Cessation |
| title_fullStr | Injectable In Situ Gelling System for Sustained Nicotine Delivery as a Replacement Therapy for Smoking Cessation |
| title_full_unstemmed | Injectable In Situ Gelling System for Sustained Nicotine Delivery as a Replacement Therapy for Smoking Cessation |
| title_short | Injectable In Situ Gelling System for Sustained Nicotine Delivery as a Replacement Therapy for Smoking Cessation |
| title_sort | injectable in situ gelling system for sustained nicotine delivery as a replacement therapy for smoking cessation |
| topic | nicotine sustained release prolonged release poloxamers design expert factorial design |
| url | https://www.mdpi.com/2310-2861/8/2/114 |
| work_keys_str_mv | AT eileenhulambukie injectableinsitugellingsystemforsustainednicotinedeliveryasareplacementtherapyforsmokingcessation AT haniabdeltawab injectableinsitugellingsystemforsustainednicotinedeliveryasareplacementtherapyforsmokingcessation AT sanjuktaduarah injectableinsitugellingsystemforsustainednicotinedeliveryasareplacementtherapyforsmokingcessation AT darrensvirskis injectableinsitugellingsystemforsustainednicotinedeliveryasareplacementtherapyforsmokingcessation AT manishasharma injectableinsitugellingsystemforsustainednicotinedeliveryasareplacementtherapyforsmokingcessation |